Hebrew University Study Demonstrates Magnetoplasmonic Nanocapsules (MAPSULES) Effective in Tumor Eradication

MAPSULES Augment Efficacy of Cancer Nanotherapies with Remote Controlled Delivery of Local Therapeutics at Precise Release Rates

An international team from The Hebrew University and the Instituto de Microelectronica de Barcelona developed metal iron-based biodegradable magnetoplasmonic nanocapsules (MAPSULES) to eradicate tumors via remote-controlled local delivery of chemotherapy at ultralow drug concentrations, while boosting drug therapeutic action and minimizing damage to surrounding tissues.

The findings of this study, published in ACS Nano Journal and featured on the cover of the latest issue, demonstrated positive therapeutic effects of MAPSULES in animals carrying human breast tumors.

Prof. Ofra Benny’s laboratory at the School of Pharmacy and the Faculty of Medicine in The Hebrew University and Dr. Borja Sepulveda and his team at the Instituto de Microelectronica de Barcelona and developed MAPSULES to guide chemotherapy directly to a target area and deliver treatment at controlled release rates. This study, led by Arnon Fluksman, a PhD student in Prof. Benny’s laboratory, fabricated and evaluated MAPSULES in various cancer cell models and found MAPSULES maximized anti-cancer activity in the tumor area while reducing side effects.

Arnon Fluksman said, “With over 18 million cancer cases worldwide in 2020, scientists and medical practitioners have grappled with advancing local drug delivery methods to improve treatment outcomes. Despite the promise of overcoming chemotherapy side effects, nanotherapies have been unable to meet expectations due to the low nanoparticle concentration that ultimately reaches the solid tumor. Our unique method enables us to remotely control the molecules with the help of a magnet, deliver drugs to the precise location of the tumor and control drug release rates.”

Results also showed that laser irradiation of MAPSULES could increase therapeutic impact by generating heat locally in the tumor site. These findings introduce the first design of a full nano-scale carrier containing large doses of chemotherapeutics with a thin external metal coating, effectively delivering chemotherapy to a solid tumor site.

“Creating an ‘Iron Dome’ of sorts for cancer, MAPSULES not only kill cancerous cells, but also protect the patient from unnecessary damage to healthy tissue, thus augmenting cancer treatment outcomes,” said Prof. Ofra Benny. “With our discovery of MAPSULES’s efficacy, we can advance our solutions and offer wide range of materials that can be manipulated and activated remotely to support a wide variety of therapies for diseases beyond cancer.”

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution